Page 2 - Nasdaq Labp News Today

Landos Biopharma (NASDAQ:LABP – Get Rating) posted its earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01, Yahoo Finance reports. Landos Biopharma Stock Performance NASDAQ:LABP opened at $0.30 on Friday. The firm has a market capitalization of $9.28 million, a PE ratio […]

Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review...

Landos Biopharma (NASDAQ:LABP – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The brokerage currently has a $2.00 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 11.11% from the […]

Landos Biopharma (NASDAQ:LABP – Get Rating) had its price target cut by stock analysts at Raymond James from $24.00 to $9.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Raymond James’ price target points to a potential upside of 400.00% from the stock’s previous […]

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...

Landos Biopharma, Inc. (NASDAQ:LABP – Get Rating) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 208,400 shares, a growth of 23.8% from the February 13th total of 168,400 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average […]

Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND...

Landos Biopharma Announces Pricing of Initial Public Offering February 03, 2021 20:13 ET | Source: Landos Biopharma, Inc. Landos Biopharma, Inc. Blacksburg, Virginia, UNITED STATES BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,...